IL-12 Receptor Positive Stem Cells for Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective identification and utilization of rare populations of hematopoietic stem cells capable of tissue repair and regeneration, particularly for therapeutic applications in regenerative medicine, such as hematopoietic tissue repair and regeneration, as well as repair of other tissue types like brain, lung, kidney, pancreatic, and cardiac tissues.
Innovation Solution
Identification and characterization of a cell population expressing the IL-12 receptor and CD34, which undergoes expansion in the presence of IL-12 ligand, and can be isolated and used for cellular transplants to repair and regenerate tissues, including the use of IL-12 receptor-positive stem cells that are radioresistant and capable of multilineage hematopoietic recovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to identify and utilize hematopoietic stem cells, then current therapeutic applications can be maintained, but the ability to effectively identify and utilize rare populations of stem cells capable of tissue repair and regeneration is limited
Solution Approach 1:
The patent uses the IL-12 receptor as an intermediary marker to identify and isolate rare hematopoietic stem cells. By targeting cells that express the IL-12 receptor, the method provides a specific and effective way to identify the desired stem cell population without requiring complex multi-marker analysis, thus improving identification precision while managing complexity
Solution Approach 2:
The patent changes the identification parameter from conventional stem cell markers to the IL-12 receptor expression status. This parameter change enables the specific identification of rare stem cell populations with tissue repair and regeneration capabilities, resolving the limitation of conventional identification methods
2Productivity
If IL-12 ligand is applied to expand stem cell populations, then significant survival and expansion properties are conferred, but the complexity of ex vivo expansion protocols increases
Solution Approach 1:
The patent applies IL-12 ligand in advance to expand and enrich the stem cell population before transplantation. This preliminary action ensures that a sufficient number of viable stem cells with enhanced survival properties are available for therapeutic application, improving productivity while the protocol complexity is managed through focused use of a single cytokine
Solution Approach 2:
The IL-12 ligand stimulates the stem cells to self-expand and self-enrich the population with desired characteristics. The stem cells respond autonomously to the IL-12 signal by increasing their numbers and enhancing their survival properties, reducing the need for complex external manipulation while achieving significant population expansion
3Adaptability or versatility
If rare stem cell populations are targeted for tissue repair, then regenerative medicine applications are enhanced, but the difficulty of detecting and measuring these rare populations increases
Solution Approach 1:
The IL-12 receptor serves as an intermediary detection target that is specifically expressed on rare stem cell populations with tissue repair capabilities. By using this receptor as a detection marker, the patent enables straightforward identification and isolation of these rare cells through flow cytometry or magnetic sorting, enhancing regenerative medicine applications while reducing detection difficulty compared to identifying cells by multiple rare characteristics
Solution Approach 2:
The patent employs fluorescently labeled antibodies against the IL-12 receptor to visually identify and sort rare stem cells. The fluorescent signal acts as a detectable marker that allows easy visualization and separation of the rare stem cell population from other cells, making detection and measurement significantly easier while maintaining high applicability to regenerative medicine
Data Source
AI summary
The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (IL-12) receptor. The present application also provides methods for making and for using the stem cells.